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Abstract
Background and Aims: Recently, several genome-wide association studies have revealed that single nucleotide
polymorphisms (SNPs) in proximity to IL28B predict spontaneous clearance of HCV infection as well as outcome following
peginterferon and ribavirin therapy among HCV genotype 1 infected patients. The present study aimed to evaluate the
impact of IL28B SNP variability on liver histology in the context of a phase III treatment trial (NORDynamIC) for treatment-
naı ¨ve patients with chronic HCV genotype 2 or 3 infection, where pretreatment liver biopsies were mandatory.
Methods: Three hundred and thirty-nine Caucasian patients had samples available for IL28B genotyping (rs12979860)o f
whom 314 had pretreatment liver biopsies that were evaluated using the Ishak protocol, allowing for detailed grading and
staging of liver histopathology.
Results: IL28B CCrs12979860 genotype in HCV genotype 3 infected patients was associated with higher ALT levels (p,0.0001),
higher AST to platelet ratio index (APRI; p=0.001), and higher baseline viral load (p,0.0001) as compared to patients with
the CT or TT genotypes. Additionally the CCrs12979860 genotype entailed more pronounced portal inflammation (p=0.02)
and steatosis (p=0.03). None of these associations were noted among HCV genotype 2 infected patients.
Conclusion: This study shows that the CCrs12979860 SNP is associated with more pronounced liver histopathology in patients
chronically infected with HCV genotype 3, which may be secondary to higher viral load. The finding that IL28B variability did
not impact on liver pathology or viral load among genotype 2 infected patients implies that IL28B may differentially regulate
the course of genotype 2 and 3 infection.
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Introduction
Hepatitis C virus (HCV) infects 170 million people worldwide
[1] and is a leading cause of chronic hepatitis, cirrhosis, and
hepatocellular carcinoma [2]. Treatment with pegylated interfer-
on-a (peg-IFN) and ribavirin results in sustained viral response
(SVR) in approximately 50% of patients infected with HCV of
genotype 1 and in 80% of those with HCV genotypes 2 or 3
[3,4,5]. Recently, several genome-wide association studies have
revealed that single nucleotide polymorphisms (SNPs) in the 19q13
region, in close proximity to three genes (IL28A, IL28B, and IL29)
encoding cytokines of the IFN-l (i.e. type III IFN) family, predict
spontaneous clearance of HCV infection [6,7] as well as SVR
following peg-IFN/ribavirin therapy among patients infected with
HCV genotype 1 [6,8,9,10]. Additionally, these polymorphisms
are strongly associated with the first phase viral decline (i.e.
reduction of HCV RNA during the first days of treatment)
irrespective of HCV genotype [11], and concomitant assessment of
pretreatment levels of systemic IP-10 and IL28B-related SNPs
augments the prediction of the first phase decline in HCV RNA
and the final therapeutic outcome [12,13].
Carriage of the favorable C allele at rs12979860 also is associated
with higher baseline viral load (8, 11, 14), which otherwise is an
established negative predictor of response to peg-IFN/ribavirin
therapy [3,4,5], possibly secondary to major allele carriage being
associated with lower intrahepatic expression of interferon-stimu-
lated genes (ISGs) [14,15]. A similarly unexpected observation is
that a C allele at rs12979860 is more common in Caucasians
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[13,16,17].
In a study of Japanese patients infected with HCV genotype 1 or
2, those homozygous for the IL28B major allele had significantly
higher inflammatory activity; also, a higher proportion of these
patients had fibrosis stage F2-4 as compared with F0-1, but
interestingly these patients also had significantly lower gamma-
GTP levels [18]. Similarly, among HCV genotype 3 infected
patients of Scandinavian descent, CC carriers at rs12979860 had
significantly higher normalized alanine aminotransferase (ALT)
levels as well as aspartate aminotransferase platelet ratio index
(APRI) than T allele carriers indicating a higher degree of
inflammation and fibrosis [19]. The aim of the present study was
to evaluate the impact of IL28B SNP variability on liver histology
in the context of a phase III treatment trial for treatment naı ¨ve
patients with chronic HCV genotype 2 or 3 infection. In this trial,
pretreatment liver biopsies were mandatory and were centrally
evaluated using the Ishak protocol, allowing for detailed grading
and staging of liver histopathology.
Materials and Methods
The NORDynamIC trial
Three hundred and eighty-two treatment naı ¨ve patients with
HCV genotype 2/3 infection were randomized at baseline to either
12 or 24 weeks of combinationtreatment with peg-IFN a-2a 180 mg
once weekly and ribavirin 800 mg daily. Baseline characteristics of
the 339 Caucasian patients that could be analyzed for IL28B
polymorphisms are detailed in Table 1. The first dose of study
medication wasadministeredunderthesupervision ofa studynurse,
and a patient diary monitored subsequent dosing. Further details
regarding this trial are provided elsewhere [20].
Classification of response
Patients were classified as having a rapid virological response
(RVR) if HCV RNA was undetectable (i.e. ,15 IU/mL) day 29,
and as achieving SVR if plasma HCV RNA was undetectable 24
weeks after completion of therapy.
IL28B genotyping
SNP rs12979860 was determined in plasma by allelic discrimi-
nation using Taqman MGB (minor groove binding) probes. The
following primers and probes were used: rs12979860: Forward,
GTGCCTGTCGTGTACTGAACCA, Reverse, AGCGCGGAG-
TGCAATTCA, Probe_C, FAM-CCTGGTTCGCGCCTT-MG-
B, Probe_T, VICCCTGGTTCACGCCT-MGB. All SNPs were at
Hardy-Weinberg equilibrium. SNP rs12979860 has previously been
reported to have a stronger association with both first phase decline
and SVR than rs8099917 and rs12980275 among Caucasian HCV
infected patients, and was thus analyzed in the present study [11].
HCV RNA quantification
Plasma was obtained using PPT-tubes and HCV RNA was
determined by RT-PCR of plasma using Cobas AmpliPrep/
COBAS TaqMan HCV Test (Roche Diagnostics, Branchburg,
NJ), which quantifies HCV RNA with a limit of detection of
#15 IU/mL. HCV RNA quantification was performed on days 0,
3, 7, 8, 29, week 8, week 12, week 24 (for those receiving 24 weeks
of therapy), and 24 weeks after completion of therapy. All samples
were frozen (270uC) and subsequently analyzed at the central
laboratory.
Liver biopsies
Liver biopsies were obtained from all patients within 24 months
prior to study entry. Only biopsies with a length exceeding 1.5 cm
and containing more than 6 portal tracts were evaluated. The
evaluation was performed in a blinded fashion by two independent
observers according to the Ishak protocol [21]. Equivocal issues
were debated after the independent scores were noted, and a
consensus score was obtained. In addition, steatosis was graded as
follows: absent=0, less than 30% of hepatocytes involved=1, 30–
70% of hepatocytes involved=2, and more than 70% of
hepatocytes involved=3 [22]. In total 314 patients could be
evaluated for both liver histology and IL28B genotype.
Fibrosis index
APRI was calculated as the ratio of normalized aspartate
aminotransferase, i.e. value divided by the upper limit of normal,
to the platelet count as previously detailed [23].
Statistical methods
Wilcoxon-Mann-Whitney U-test, Kruskal-Wallis test, and Chi
squared (x
2) tests were utilized to evaluate relationships between
groups. All statistical analyses were performed using IBM SPSS
statistics version 19.0 (IBM Corporation, Somers, NY) and
StatView (version 5.0, SAS Institute Inc., Cary, NC, USA) software
packages. All reported p-values are two-sided, and p-values,0.05
were considered significant.
Ethical considerations
Written informed consent was obtained from each participating
patient. Ethics committees in each participating country approved
Table 1. Baseline Characteristics with Patients Grouped According to HCV genotype and IL28B Genetic Variations (rs12979860).
HCV genotype 2 HCV genotype 3
CC CT TT P CC CT TT P
n=48 n=40 n=10 n=101 n=113 n=27
Age (years)
a 49 (41–54) 47 (41–56) 48 (35–53) NS 41 (32–48) 40 (33–48) 40 (29–46) NS
Gender (Male/Female)
b 28/20 24/17 6/4 NS 69/37 68/49 14/13 NS
BMI (kg/m
2)
a 25 (22–27) 25 (24–28) 25 (23–26) NS 25 (23–28) 26 (23–29) 27 (23–28) NS
Fibrosis Stage (Ishak 0/1/2/3/4/5/6)
b 2/8/11/12/7/4/3 0/5/10/10/7/2/4 2/0/4/2/1/0/1 NS 2/8/33/28/9/7/10 3/17/36/26/16/4/6 1/6/6/5/3/2/0 NS
HOMA-IR
a 2.7 (1.4–4.4) 2.4 (1.1–7.0) 2.5 (1.3–9.8) NS 2.2 (1.4–5.0) 2.9 (1.9–6.6) 3.8 (2.0–7.7) NS
Alkohol consumption (drinks/day)
a 0.0 (0.0–0.5) 0.1 (0.0–0.4) 0.1 (0.0–0.4) NS 0.1 (0.0–0.4) 0.0 (0.0–0.4) 0.0 (0.0–0.3) NS
Data presented as median (25
th–75th percentile)
a or n
b.
doi:10.1371/journal.pone.0029370.t001
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Sweden (Regionala etikpro ¨vningsna ¨mnden i Go ¨teborg), Regional
Committee for Ethics in Medical Research, Bergen, Norway
(Regionaletisk komite for medisinsk og helsefaglig forskning i
Bergen), The Scientific Ethical Committee for the Region of
Middle Jylland, Viborg, Denmark (Den Videnskabsetiske Komite ´
for Region Midtjylland), The Scientific Ethical Committee for the
Region of South Denmark, Vejle, Denmark (Den Videnskabse-
tiske Komite ´ for Region Syddanmark), and the Ethics Committee,
Department of Medicine for the Hospital District of Helsinki and
Uusimaa, Finland (Etiska kommitte ´n fo ¨r inva ¨rtesmedicin)). The
study has been registered at the NIH trial registry (Clinical-
Trials.gov Identifier: NCT00143000).
Results
A strong association was noted between IL28B genotype and
pretreatment normalized ALT (median 2.4, 2.3, and 1.6 for CC,
CT, and TT respectively) and as well as APRI, a biomarker of
liver fibrosis [23], (median 0.7, 0.6, and 0.5 for CC, CT, and TT
respectively) among HCV genotype 3 infected patients, with
homozygous TT carriers having the lowest levels (p,0.0001 and
p=0.001 respectively, Kruskal-Wallis test; Figure 1). With regards
to ALT, CT carriers were more similar to CC than TT (CC vs.
CT p=0.6, CT vs. TT p=0.0001, and CC vs. TT p,0.0001,
Mann-Whitney U-test), but when evaluating APRI, CT patients
were intermediary (CC vs. CT p=0.03, CT vs. TT p=0.07, and
CC vs. TT p=0.0015, Mann-Whitney U-test). This was mirrored
by a significantly higher proportion of these patients having lower
portal inflammation grades in their pretreatment liver biopsies, in
contrast to homozygous CC carriers who had the highest grades
(p=0.02, Chi-squared test; Figure 2C). A similar non-significant
trend was noted for interface hepatitis grade and fibrosis stage,
with CC carriers having the highest grades and stages. No such
trend was noted for the grade of lobular inflammation or confluent
necrosis. In accordance with the observation for portal inflamma-
tion, homozygous CC carriers had the most pronounced steatosis
and homozygous TT carriers had the least (p=0.03, Chi squared
test; Figure 2D). Because APRI is a continuous variable in contrast
to fibrosis stage, which is ordered categorical data derived from
liver biopsies prone to sampling error, different statistical methods
are applicable, which may explain the significant association
between IL28B genotype and APRI for genotype 3 in contrast to a
non-significant trend for fibrosis stage.
The associations between IL28B genotype and ALT, APRI,
portal inflammation grade, and steatosis observed among HCV
genotype 3 infected patients, were not significant among HCV
genotype 2 infected patients nor were any such trends noted
among these latter patients. It should, however, be noted that the
Figure 1. Impact of IL28B (rs12979860) on normalized ALT and AST to platelet ratio index (APRI) among HCV genotype 2 and 3
infected patients. Box plots displaying the 10
th,2 5
th,5 0
th,7 5
th, and 90
th percentiles and p-values obtained using Kruskal-Wallis test.
doi:10.1371/journal.pone.0029370.g001
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were significantly older than those infected with HCV genotype 3
(mean age 47.2 vs. 39.8 years for HCV genotype 2 and 3
respectively, P,0.0001, Mann-Whitney U-test), and the number
of patients enrolled with HCV genotype 2 was smaller than
genotype 3 (98 vs. 241).
The HCV genotype 3 infected homozygous CC carriers had
significantly higher baseline viral load (mean 6.3, 5.9, and 5.9
log10 IU/mL for CC, CT, and TT respectively, p,0.0001,
Kruskal-Wallis test; Figure 3C) as well as first phase decline as
measured by the decline in HCV RNA during the first three days of
interferon/ribavirin therapy (mean 2.1, 1.7, and 1.9 log10 IU/mL
for CC, CT, and TT respectively, p=0.0005, Kruskal-Wallis test;
Figure 3D). In contrast, no such associations were noted among
HCV genotype 2 infected patients. Additionally no significant
associations were noted among IL28B genotype and the likelihood
of achieving SVR irrespective of HCV genotype. Further details
regarding the impact of IL28B genotype on the viral kinetic during
therapy in this trial are provided elsewhere [24].
Lower baseline HCV RNA levels were significantly associated
with lower portal inflammation (p=0.01, Chi-squared test) and
steatosis grades (p,0.0001, Chi-squared test). Subgroup analyses
revealed that these associations were significant for genotype 3
(p=0.003 for portal inflammation and P,0.0001 for steatosis,
Chi-squared test; Figure 4C and D respectively), but not for HCV
genotype 2. These associations remained significant when
controlling for IL28B genotype.
Discussion
In spite of the beneficial treatment effects among patients
carrying the C allele carriage at rs12979860, little is known
regarding its impact on the natural history of chronic HCV. Abe et
al. reported that among Japanese patients infected with HCV
genotype 1 or 2, patients with homozygous carriage of the IL28B
major allele had significantly higher inflammatory activity and
higher fibrosis stage, indicating that this SNP genotype may not be
beneficial outside the context of therapeutic intervention [18].
Similarly in a treatment trial by Moghaddam et al. involving HCV
genotype 3 infected Caucasian patients, CC carriers at rs12979860
had significantly higher normalized ALT levels and APRI scores
than CT or TT carriers, however, liver biopsy evaluations were
not reported [19]. In this context the main finding of the present
study was a significant association between CC carriage at
Figure 2. Association between IL28B (rs12979860) and portal inflammation grade (Ishak protocol) and steatosis grade among HCV
genotype 2 and 3 infected patients. Histogram displaying the proportion of patients, and p-value obtained using Chi-squared test.
doi:10.1371/journal.pone.0029370.g002
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and steatosis among HCV genotype 3 infected patients, and that
these associations appeared to be secondary to a significantly
higher baseline viral load. Indeed it has previously been reported
that among HCV genotype 3 infected patients, steatosis is more
prevalent and pronounced than in other HCV genotypes [22,25]
due to impaired lipid export from infected hepatocytes [26,27]
possibly mediated by inhibition of microsomal triglyceride transfer
protein (MTP) [28,29] or due to increased availability of free fatty
acids by reduced oxidation or by increased de novo synthesis
[30,31,32,33] of the genotype 3 core protein. Additionally the
presence of steatosis in HCV genotype 3 infection is associated
with higher baseline HCV RNA levels [25,34], negatively impacts
the clearance of HCV RNA during the initial 12 weeks of therapy
[34], and entails accelerated fibrosis progression [22] indicative of
a likely cytopathic effect of HCV genotype 3 virus. Moreover, it
was recently reported that the cumulative mortality of HCV
genotype 3 infected US Department of Veterans Affairs (VA)
patients failing to achieve SVR after therapy was higher than
among non-SVR patients infected with genotypes 1 or 2 [35]
possibly secondary to HCV genotype 3 associated steatosis and
ensuing liver damage.
In the setting of therapeutic intervention for HCV genotype 2 or
3, uncertainty prevails regarding the benefit of favorable IL28B
allele carriage. Sarrazin et al. reported increased SVR rates
following therapy among HCV genotype 2 or 3 infected
Caucasian CC rs12979860 carriers as compared to carriers of
the T allele [36]. In contrast Mangia et al. noted an association
between IL28B genotype and SVR only among HCV genotype 2
or 3 infected patients failing to achieve RVR [37]. Yu et al.
reported a significantly higher rate of achieving RVR but not SVR
among Asian homozygous TT rs8099917 carriers infected with
HCV genotype 2 [38] and Moghaddam et al. noted similar results
among HCV genotype 3 infected Caucasian CC rs12979860
carriers [19]. In the present study a significantly improved first
phase decline in HCV RNA was noted among homozygous CC
carriers infected with HCV genotype 3 but not among genotype 2.
However, the higher baseline viral load among these genotype 3
infected patients essentially negated most of the favorable decline
in HCV RNA observed during the initial three days of therapy.
The reason for failing to observing an association between
CCrs12979860 and the first phase decline in HCV RNA among
the HCV genotype 2 infected patients enrolled in the present study
is not clear, but may indicate that IL28B SNP polymorphisms have
a more pronounced therapeutic impact among HCV genotype 3
than genotype 2 infected Caucasian patients of Scandinavian
descent.
In conclusion, the present study demonstrated an association
between CC carriage at rs12979860 and ALT, APRI, portal
inflammation grade, and steatosis among HCV genotype 3
infected patients, and that this association may be secondary to
the significantly higher baseline viral load. In this light, analysis of
IL28B genotype may be beneficial among HCV genotype 3
infected patients so as to encourage homozygous CC rs12979860
carriers to initiate therapy. Additionally the finding that IL28B
variability did not impact on liver histopathology or viral load
Figure 3. Impact of IL28B (rs12979860) on baseline viral load and decline in mean HCV RNA day 0–3 among HCV genotype 2 and 3
infected patients. Box plots displaying the 10
th,2 5
th,5 0
th,7 5
th, and 90
th percentiles, and p-values obtained using Kruskal-Wallis test.
doi:10.1371/journal.pone.0029370.g003
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differentially regulate the course of genotype 2 and 3 infection.
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